Abstract |
Eighty-eight consecutive patients undergoing bone marrow transplantation (BMT) from July 1985 to June 1993 were retrospectively studied for their bone marrow engraftment characteristics with and without granulocyte colony stimulating factor ( R-metHUG-CSF, Filgrastim). Seventy-seven patients (87.5%) achieved engraftment, 55 out of 65 patients (84.6%) without R-metHUG-CSF and 22 out of 23 patients (95.7%) with R-metHUG-CSF (P > 0.1). The mean duration of administration of R-metHUG-CSF was 15.1 days. The mean time to engraftment was significantly reduced by 7.1 days, from 20.5 days to 13.4 days (P < 0.0001). The mean duration of hospitalisation was also significantly reduced by 11.1 days, from 52.6 days to 41.5 days (P < 0.0001). There were no side effects directly attributable to R-metHUG-CSF encountered. We conclude that R-metHUG-CSF is very effective in shortening the duration of neutropenia in the immediate post-BMT period with lesser BMT morbidity, earlier discharge from hospital and lower cost of BMT. We recommend a routine 2-week course beginning on the day after marrow infusion.
|
Authors | G K Teoh, P H Tan, Y T Goh |
Journal | Annals of the Academy of Medicine, Singapore
(Ann Acad Med Singap)
Vol. 23
Issue 6
Pg. 823-7
(Nov 1994)
ISSN: 0304-4602 [Print] Singapore |
PMID | 7537949
(Publication Type: Journal Article)
|
Chemical References |
- Recombinant Proteins
- Granulocyte Colony-Stimulating Factor
- Filgrastim
|
Topics |
- Adult
- Bone Marrow Transplantation
(adverse effects)
- Female
- Filgrastim
- Granulocyte Colony-Stimulating Factor
(administration & dosage, therapeutic use)
- Humans
- Length of Stay
(statistics & numerical data)
- Male
- Neutropenia
(etiology, therapy)
- Recombinant Proteins
(administration & dosage, therapeutic use)
- Retrospective Studies
- Time Factors
|